Navigation Links
Biotech Posts Strong Third Quarter Performance as Capital Markets Go on a Tear
Date:10/1/2010

down 18 percent YTD), Celgene ($26.47B, up 12 percent for September, up 13.4 percent for the quarter and up 3.4 percent YTD), Genzyme ($18.04B, up 1 percent for September, up 39.4 percent for the quarter and up 44.2 percent YTD), and Biogen ($13.56B, up 4.3 percent for September, up 18.3 percent for the quarter and up 3.4 percent YTD).
  • 55 biotech companies (18 percent) have market caps greater than $1B (compared to 49 companies at the same time last year)
  • 98 biotech companies (32 percent) have market caps less than $100M compared to 39 percent (122 companies) at the same time last year.

  • (*The October edition of the monthly, subscription-based Burrill Report has a breakdown of the industry's third quarter 2010 performance.)

    Note: Tables on the Burrill Biotech Indices and US biotech financings for Q3 2010 are available on request.


    '/>"/>
    SOURCE Burrill & Company
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. Kibow Biotech Releases Results of Pilot Scale Study of Its Probiotic Formulation for Kidney Health
    2. The Number of Biotechnology Companies has Only Decreased by 10% Despite the Crisis
    3. Vaccinogen Names Veteran Biotech Executive Michael Kranda President & CEO
    4. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
    5. NEURO-BIOTECH DISCLOSES ITS LIST OF LICENSES
    6. Nanobiotechnology experts join forces to improve TB testing
    7. Sanofi Pasteur to Acquire VaxDesign, a U.S. Biotechnology Company
    8. PROLOR Biotechs Longer-Acting Human Growth Hormone Data Selected for Presentation at 5th International Congress Of The Growth Hormone Research Society and IGF Society
    9. Kevin Kruse Named Executive Director of the Society of Pharmaceutical and Biotech Trainers
    10. Oxford Resource Partners, LP and Mendel Biotechnology, Inc. Announce a Miscanthus Biomass Pilot Project in Ohio
    11. Neuro-Biotechs Solution for a Doctor near You: Early Detection for Alzheimers and Chronic Fatigue Syndrome!
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... -- PharmaBoardroom,s new report, , Healthcare ... for free download , digs deep into this vibrant ... the sector today. One area where ... developing a homegrown pharmaceutical manufacturing base, even if the government,s ... way off. A cursory comparison with neighboring Morocco ...
    (Date:12/22/2014)... , Dec. 22, 2014   Synthetic ... developer of pathogen-specific therapies for serious infections ... the microbiome, today announced positive topline safety ... clinical trial of SYN-004, the Company,s investigational ... Clostridium difficile (C. difficile) infection, ...
    (Date:12/22/2014)... The American Journal of ... research, reviews and editorials addressing developments and pathways ... published a provocative article exploring the role of ... potential treatment of prostate cancer. , The ... the possibility that there could be a connection ...
    (Date:12/19/2014)... 19, 2014 BioPlus Specialty Pharmacy ... announces the promotion of Nick Maroulis, Pharm.D. to the ... Services. , In this position, Dr. Maroulis will ... managing the directors of our multi-site pharmacies as the ... 1997 and during that time he has served in ...
    Breaking Biology Technology:PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
    ... ROCKVILLE, Md., May 5 Sequella, Inc., a clinical-stage ... today the start of its Phase 1B trial for ... volunteers. SQ109, a new diamine antibiotic intended to replace ... and simplify patient therapy, was granted U.S. FDA Fast ...
    ... Mass., May 5 Syrinx Consulting Corporation ... that delivers easy-to-use .Net and SharePoint applications ... contract for approximately $100,000 with a leading biopharmaceutical company ... migrating thousands of users and gigabytes of data from ...
    ... Breakthrough biotechnology research is providing new applications ... and diabetes, two leading health concerns among consumers. ... Advana Science, www.advanascience.com , will ... this dynamic consumer healthy category at VitaFoods International ...
    Cached Biology Technology:Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109 2Syrinx Wins Contract with Leading Pharmaceutical Company for SharePoint 2007 Services 2Industry Expert Reveals Cutting Edge Biotechnology Science for Nutraceutical and Functional Food Applications 2
    (Date:12/19/2014)... Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... July 2012, Apple introduced the fingerprint reading feature ... only device of Apple incorporating such a feature, ...
    (Date:12/17/2014)... Dec. 15, 2014 The Defense Logistics ... easier to detect and prevent counterfeit microcircuits from ... the agency started performing an in-house microcircuit anti-counterfeit ... the authenticity of purchased microcircuits while increasing their ... control measures will be conducted at DLA,s Electronics ...
    (Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "Global Facial Recognition Market ... http://photos.prnewswire.com/prnh/20130307/600769 Facial ... of individuals. Facial recognition system measures the overall ... jaw edges, mouth, and the distance between eyes. ...
    Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
    ... fund structured by JPMorgan Chase & Co. (NYSE: JPM) ... the first time, allow individual and institutional investors the ... the potential to save millions of lives in low-income ... pioneering group of investors including anchor support from ...
    ... imply that it is hard to fool the brain by ... sweet solutions is driven to a great extent by the ... is attributed to sugars compared to artificial sweeteners. Professor ... School of Medicine USA, says:,"The consumption of high-calorie beverages is ...
    ... vaccine after using the 2009 pandemic as a natural experiment ... Researchers at Imperial College London asked volunteers to donate ... underway and report any symptoms they experienced over the next ... severe illness had more CD8 T cells, a type of ...
    Cached Biology News:New investment fund will advance late-stage vaccines, other global health technologies 2New investment fund will advance late-stage vaccines, other global health technologies 3New investment fund will advance late-stage vaccines, other global health technologies 4The brain cannot be fooled by artificial sweeteners 2Scientists closer to universal flu vaccine after pandemic 'natural experiment' 2